Highest-materiality recent filing
Revvity Q2 adjusted EPS $1.41 beats prior year; divests China IDX for up to $200M
Q2 revenue $730M (+1.4% reported); GAAP EPS $0.48; adjusted EPS $1.41 (+19% YoY).
Revvity Q1 adj EPS $1.06 beats $1.01 YoY; revenue $711M +7%; plans China IDX divestiture
Q1 GAAP EPS $0.37 vs $0.35 YoY; adjusted EPS $1.06 vs $1.01; revenue $711M (+7% YoY).
Revvity Q4 revenue $772M (+6% YoY), adj EPS $1.70 vs $1.42; initiates 2026 guidance
Q4 GAAP EPS $0.87 vs $0.78; adjusted EPS from cont. ops. $1.70 vs $1.42.
Revvity pre-announces Q4 2025 revenue ~$772M, adj. EPS above guidance
Q4 2025 revenue expected ~$772M, reported +6% and organic +4% YoY.
Revvity Q3: revenue $699M (+2%), GAAP EPS $0.40, adjusted EPS $1.18; raises FY guidance
Revenue $699M, up 2% reported / 1% organic; GAAP EPS $0.40 vs $0.77 a year ago.
Revvity Q2 revenue $720M (+4% reported), GAAP EPS $0.46, adjusted EPS $1.18; updates FY2025 guidance
Revenue $720M, +4% reported and +3% organic; GAAP EPS $0.46 vs $0.45 prior year.
Revenue $665M, up 2% reported and 4% organic YoY.
Revvity Q4 revenue $729M (+6% organic), adj EPS $1.42; FY adj EPS $4.90
Q4 revenue $729M (+5% reported, +6% organic); GAAP EPS $0.78 (vs $0.64); adjusted EPS $1.42 (vs $1.25).
Revvity provides preliminary Q4 revenue ~$730M, 6% organic growth; EPS guidance reaffirmed
Q4 preliminary revenue ~$730M; reported growth ~5%, organic ~6% vs. prior year.
Revvity Q3 GAAP EPS $0.77, adj. EPS $1.28; raises FY guidance; $1B buyback
Revenue $684M, +2% reported and organic YoY; GAAP operating margin 14.3% vs 10.3%.
Revvity Q2 2024: GAAP EPS $0.45, Adj EPS $1.22; raises full-year adj EPS guidance
Revenue $692M (-2% reported, -1% organic); GAAP EPS $0.45 vs $0.28 YoY.
Revvity Q1 revenue down 4% to $650M; GAAP EPS $0.21 vs $4.50; reaffirms FY guidance
Revenue $650M, -4% reported, -3% organic; GAAP EPS $0.21 vs $4.50 (prior year included large gain from discontinued ops).
Revvity Q4 revenue $696M (-6%), adjusted EPS $1.25 vs $1.41; full year adjusted EPS $4.65 vs $6.92
Q4 GAAP EPS $0.64 vs $1.01; adjusted EPS $1.25 vs $1.41; revenue down 6% reported, 7% organic.
Q4 2023 revenue expected at least $690M, reported organic revenue decline of approx. 7% and non-COVID organic decline of 4% year-over-year.
Revvity Q3 revenue $671M, -7% organic; adj EPS $1.18; updates FY23 guidance
GAAP EPS $0.08 vs $0.67 a year ago; GAAP revenue $671M (-6% reported, -7% organic).
Revvity Q2 revenue $709M, down 21%; GAAP EPS $0.28, adjusted EPS $1.21
Revenue $709M, down 21% reported and 20% organic; non-COVID organic growth of 6%.
Revenue $675M, down 30% reported (-27% organic); non-COVID organic growth 6%.
Sale of Business (Applied, Food, Enterprise Services) closed Mar 13, 2023; cash consideration ~$2.136B, subject to adjustments.
PerkinElmer Q4 revenue $741M; GAAP EPS $0.85; combined adjusted EPS $1.70; initiates 2023 guidance
Q4 GAAP revenue from continuing ops $741M, down 28% reported; 8% non-COVID organic growth.
PerkinElmer expects Q4 2022 results to meet or exceed prior guidance; earnings call Feb 14
Q4 2022 results expected to meet or exceed guidance provided on Nov 8, 2022.
PerkinElmer Q3 revenue $712M (-17% reported); pro forma adj EPS $1.51
GAAP revenue $712M (down 17% YoY); GAAP EPS from continuing ops $0.55 vs $0.94.
PerkinElmer sees Q3 organic revenue growth and adjusted EPS above prior guidance
Preliminary Q3 2022: organic revenue growth and adjusted EPS expected to exceed prior guidance.
CFO James Mock resigns; Maxwell Krakowiak named new CFO effective Sep 6, 2022
James M. Mock resigns as CFO and terminates employment on Sep 5, 2022.
PerkinElmer sells Applied, Food & Enterprise Services to New Mountain Capital for up to $2.45B
Cash consideration up to ~$2.45B; ~$2.3B at closing including $75M deferred for brand transfer.
PerkinElmer Reports Q2 2022 Results and Plans to Divest Applied, Food, and Enterprise Services
Second quarter revenue was $1.23 billion with 0% reported growth and 8% non-COVID organic growth.
PerkinElmer Q1 revenue $1.26B; GAAP EPS $1.40, adjusted EPS $2.41; all down YoY; raises FY guidance
Revenue $1.26B, down 3.8% YoY from $1.31B.
PerkinElmer Q4 GAAP EPS $1.41 vs $3.38 YoY; revenue flat at $1.36B; organic growth -9%
Q4 2021 revenue $1.36B, 1% reported growth, -9% organic growth year-over-year.
PerkinElmer raises Q4 2021 outlook: adj. EPS at least $2.40, non-COVID organic growth ~10%
Q4 2021 adjusted EPS expected at least $2.40, above prior guidance.
BioLegend FY2020 audited: revenue $241.9M, net income $90.6M
BioLegend net sales $241.9M, gross profit $169.7M, operating income $109.6M, net income $90.2M.
PerkinElmer Q3 revenue $1.17B (+21%) adj EPS $2.31 beats; raises FY guidance
Revenue $1.17B, up 21% reported, 12% organic; GAAP EPS $1.11, adj EPS $2.31.
PerkinElmer closes $5.25B BioLegend acquisition; issues ~14.1M shares as stock consideration
Aggregate purchase price ~$5.25B; paid 59.5% cash and 40.5% stock valued at $156.3561/share.
PerkinElmer issues $2.3B in senior notes to finance BioLegend acquisition
Issued $2.3B aggregate: $500M 0.55% notes due 2023, $800M 0.85% due 2024, $500M 1.90% due 2028, $500M 2.25% due 2031.
PerkinElmer enters $500M delayed draw term loan to partly fund BioLegend acquisition
Unsecured term loan facility for $500M to fund portion of BioLegend acquisition, refinance BioLegend debt, and pay fees.
PerkinElmer to acquire BioLegend for $5.25B; expects $0.30 adjusted EPS accretion in first full year
Purchase price ~$5.25B; 59.5% cash and 40.5% stock at $156.3561/share.
PerkinElmer Q2 revenue $1.228B (+51%); raises guidance; to acquire BioLegend
Revenue $1.228B, +51% reported, +41% organic; GAAP EPS $2.19, adjusted EPS $2.83.
On January 25, 2024, the Board elected Michael A. Klobuchar and Sophie V. Vandebroek to serve on the Board, effective February 1, 2024.
On January 25, 2024, the Board elected Michael A. Klobuchar and Sophie V. Vandebroek to serve on the Board, effective February 1, 2024.
On January 25, 2024, Dr. Sylvie Grégoire, a member of the Board of Directors (the “Board”) of Revvity, Inc. (“Revvity” or the “Company”) notified the Company of her decision not to stand for re-election to the Board at the annual meeting of shareholders of the Company scheduled to occur on April 23, 2024.
On August 16, 2022, the Company’s Board of Directors (the “Board”) appointed Maxwell Krakowiak to serve as its Senior Vice President and Chief Financial Officer, effective as of September 6, 2022.
James M. Mock, the Senior Vice President and Chief Financial Officer of PerkinElmer, Inc. (“PerkinElmer” or the “Company”), notified the Company that he is resigning as the Company’s Chief Financial Officer and terminating his employment effective as of September 5, 2022.
On July 22, 2022, the Board of Directors (the “Board”) of PerkinElmer, Inc. (“PerkinElmer” or the “Company”) elected Dr. Michelle McMurry-Heath to serve on the Board, effective immediately.
Max materiality 0.90 · Median 0.70 · Most common event earnings